Evidence map›Paper›PMID 37342419›Full record

ArticleSAGE open medical case reports2023

Ixazomib-induced Sweet's syndrome: A case report.

Jeanne Bellemare, Hannah Laure El Fassy, Alexandra Mereniuk

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jeanne BellemareDivision of Dermatology, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, QC, Canada.ORCID https://orcid.org/0000-0003-0937-6103
Hannah Laure El FassyDivision of Immunology-Allergy, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, QC, Canada.
Alexandra MereniukDivision of Dermatology, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, QC, Canada.ORCID https://orcid.org/0000-0002-4090-7833
Hôpital du Sacré-Cœur de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ixazomib, a proteasome inhibitor commonly used for the treatment of multiple myeloma, is a rare cause of Sweet's syndrome. We present a 62-year-old man who developed drug-induced Sweet's syndrome during his fifth cycle of ixazomib for treatment of refractory multiple myeloma. Monthly rechallenge led to the recurrence of symptoms. The patient was successfully treated with addition of weekly corticosteroids and resumed his cancer treatment.

Indexed as

case reportdrug-inducedixazomibmultiple myelomaSweet’s syndrome

Identifiers

PMID37342419
PMCPMC10278404
OpenAlexW4380990531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.